Get the Stockscreener App
44.42
0.57%
0.25
After Hours:
45.00
0.58
+1.31%
Exelixis Inc stock is traded at $44.42, with a volume of 3.56M.
It is up +0.57% in the last 24 hours and up +1.23% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$44.17
Open:
$44.45
24h Volume:
3.56M
Relative Volume:
1.29
Market Cap:
$11.28B
Revenue:
$2.32B
Net Income/Loss:
$782.57M
P/E Ratio:
15.96
EPS:
2.7838
Net Cash Flow:
$875.84M
1W Performance:
-1.14%
1M Performance:
+1.23%
6M Performance:
+10.03%
1Y Performance:
+11.50%
1-Day Range:
$44.13
$45.21
1-Week Range:
$43.50
$45.41
52-Week Range:
$33.76
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.42 | 11.22B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Exelixis Q1 2026 slides: revenue grows 10%, zanzalintinib advances - Investing.com
Exelixis Q1 Earnings Call Highlights - Yahoo Finance
Transcript : Exelixis, Inc., Q1 2026 Earnings Call, May 05, 2026 - marketscreener.com
Earnings call transcript: Exelixis beats Q1 2026 forecasts, stock rises - Investing.com
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Exelixis Posts Strong Q1 Results, Expands Share Buybacks - TipRanks
Exelixis (EXEL) Tops Q1 Earnings Estimates - Yahoo Finance
Exelixis (EXEL) Q1 2026 Earnings Transcript - The Globe and Mail
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum - ChartMill
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.58B - marketscreener.com
Exelixis Q1 Non-GAAP Earnings, Revenue Rise - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76 - marketscreener.com
Exelixis: Q1 Earnings Snapshot - kare11.com
Exelixis (NASDAQ: EXEL) boosts Q1 2026 earnings, cash and buybacks - Stock Titan
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can RCC franchise weather competition? - Investing.com
MSN Money - MSN
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - Caledonian Record
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative - Yahoo Finance
Behavioral Patterns of EXEL and Institutional Flows - Stock Traders Daily
Earnings Preview: Exelixis to Report Financial Results Post-market on May 05 - Moomoo
Vanguard Capital Management (NASDAQ: EXEL) reports 5.09% stake - Stock Titan
Exelixis (EXEL) is a top-ranked value stock: Should you buy? - MSN
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC - ChartMill
Will Exelixis (EXEL) beat estimates again in its next earnings report? - MSN
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Why Exelixis (EXEL) is a top value stock for the long term - MSN
Do Options Traders Know Something About Exelixis Stock We Don't? - msn.com
Exelixis, Inc. (EXEL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings Spark Investor Interest - DirectorsTalk Interviews
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Exelixis Inc (BSP:E2XE34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Exelixis (BSP:E2XE34) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BSP:E2XE34 ROE %: 45.26% — 110% Above Median - GuruFocus
Exelixis Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Exelixis Inc (BSP:E2XE34) Stock Today? - GuruFocus
Exelixis (BSP:E2XE34) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
Exelixis Inc (BSP:E2XE34) Dividend - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price, Trades & News - GuruFocus
Exelixis Inc (BSP:E2XE34)Valuation Measures & Financial Statistics - GuruFocus
Exelixis Inc Stock Baskets | BSP:E2XE34 - GuruFocus
Exelixis Inc Stock Operating Data - GuruFocus
Exelixis Inc Stock Warning Signs - GuruFocus
Exelixis Inc (BSP:E2XE34) Competitors 2026 - GuruFocus
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):